Translumina intends to leverage the platform to introduce a basket of owned and partnered products in the German market
Translumina, a global leader in interventional cardiovascular medical devices with a manufacturing presence in Germany and India, announced the acquisition of Munich-based Lamed. With this acquisition, Translumina has taken a step further towards its stated goal of providing a comprehensive cardiovascular portfolio at scale across key markets globally.
Established in 1989, Lamed is a leading market access platform for vascular and cardiovascular products. It covers 1,000+ hospitals through its GPO network in Germany, which is the largest interventional cardiology market in Europe; the company exclusively distributes a portfolio of differentiated products for a marquee international supplier base. Lamed’s seasoned senior management team brings 30+ years of experience and deeply entrenched ecosystem relationships.
Translumina intends to leverage the platform to introduce a basket of owned and partnered products in the German market.
Lazaros Ayvatoglou, Founder of Lamed, is convinced to have chosen the right partner in Translumina for further development of its well-established platform. He said, “After the initial discussion, it was clear that both businesses enrich each other with manifold growth opportunities. I am happy to have found a partner that builds on the established foundation of Lamed for a successful future.”
“This acquisition is of strategic importance and gives us significant access to vascular and cardiovascular markets in Germany, which is one of the largest in Europe. The synergy of our unique technologies and market penetration of Lamed shall create a formidable business opportunity for us,” said Gurmit Singh Chugh who along with Punita Sharma founded Translumina in 2010.
Arjun Oberoi, MD, Everstone Capital, said, “Translumina’s acquisition of Lamed positions us for accelerated growth in Germany’s thriving peripheral interventional and vascular surgery sector. With access to major GPOs and hospitals in the largest European medical devices market, we are poised to excel in interventional cardiology, peripheral vascular, and structural heart disease segments.”